LAZCLUZE Label Updated for First-Line NSCLC with EGFR Mutations

The U.S. Food and Drug Administration (FDA) announced a label revision for LAZCLUZE (lazertinib) on 2026-05-05. This update includes a new indication for LAZCLUZE, in combination with amivantamab, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations.

Background

Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer diagnoses and is a leading cause of cancer-related mortality globally. A critical subset of NSCLC patients, particularly those with adenocarcinoma histology, often harbor activating mutations in the epidermal growth factor receptor (EGFR) gene. These EGFR mutations, such as exon 19 deletions or L858R substitutions, are well-established oncogenic drivers that promote uncontrolled cell growth and survival. Targeted therapies designed to inhibit EGFR have significantly improved outcomes for these patients, shifting the treatment paradigm from traditional chemotherapy.

What this means

The updated indication for LAZCLUZE, used in combination with amivantamab, marks an important development for the management of EGFR-mutated NSCLC. Specifically, its approval for first-line treatment means that this combination therapy can now be considered as an initial therapeutic approach for adult patients with locally advanced or metastatic disease who have these specific EGFR mutations. This provides clinicians with an additional, potentially more effective, option to initiate treatment, aiming to improve patient outcomes by targeting the disease at an earlier stage of therapy. The combination approach suggests a strategy to potentially overcome resistance mechanisms or enhance efficacy compared to monotherapy.

Source

Information regarding this label revision was obtained from the U.S. Food and Drug Administration (FDA) via a DailyMed update. The revised indication and usage for LAZCLUZE, in combination with amivantamab, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, became effective on 2026-05-05 and is publicly available on dailymed.nlm.nih.gov.